EntryPoint Capital LLC Buys New Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

EntryPoint Capital LLC purchased a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 24,903 shares of the biotechnology company’s stock, valued at approximately $313,000.

Other large investors also recently modified their holdings of the company. Intech Investment Management LLC bought a new stake in Rocket Pharmaceuticals during the third quarter worth about $527,000. Charles Schwab Investment Management Inc. raised its stake in shares of Rocket Pharmaceuticals by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company’s stock worth $10,524,000 after purchasing an additional 20,322 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Rocket Pharmaceuticals by 9.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 152,293 shares of the biotechnology company’s stock valued at $2,813,000 after buying an additional 12,680 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Rocket Pharmaceuticals by 9.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,767 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 1,675 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Rocket Pharmaceuticals by 1.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company’s stock valued at $2,210,000 after buying an additional 1,561 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on RCKT shares. Scotiabank increased their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. The Goldman Sachs Group cut their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. BMO Capital Markets began coverage on Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. Canaccord Genuity Group cut their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Finally, Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 target price for the company. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.00.

Rocket Pharmaceuticals Trading Up 2.5 %

Shares of Rocket Pharmaceuticals stock opened at $7.88 on Friday. Rocket Pharmaceuticals, Inc. has a 52-week low of $7.64 and a 52-week high of $27.30. The stock has a market cap of $840.24 million, a PE ratio of -2.87 and a beta of 1.03. The firm has a 50-day moving average of $9.68 and a 200-day moving average of $13.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. As a group, sell-side analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.